Interleukin Genetics (ILIU) 10-Q 12 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 11, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Entity Registrant Name	INTERLEUKIN GENETICS INC
Entity Central Index Key	1,037,649
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ILIU
Entity Common Stock, Shares Outstanding		172,887,221

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 6,270,644	$ 11,466,807
Accounts receivable from related party	40,603	23,544
Trade accounts receivable	5,305	14,013
Inventory	159,093	171,575
Prepaid expenses	531,628	504,719
Total current assets	7,007,273	12,180,658
Fixed assets, net	658,899	773,779
Intangible assets, net	137,523	195,765
Other assets	99,135	116,919
Total assets	7,902,830	13,267,121
Current liabilities:
Accounts payable	576,210	513,927
Accrued expenses	455,299	343,225
Deferred revenue	2,925,725	3,154,498
Total current liabilities	3,957,234	4,011,650
Long Term Debt	4,790,891	4,738,614
Total Liabilities	$ 8,748,125	$ 8,750,264
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.001 par value - 450,000,000 and 300,000,000 shares authorized at September 30, 2015 and December 31, 2014, respectively; 172,841,047 and 172,683,342 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	$ 172,843	$ 172,686
Additional paid-in capital	126,107,664	125,434,483
Accumulated deficit	(127,125,802)	(121,090,312)
Total stockholders’ equity (deficit)	(845,295)	4,516,857
Total liabilities and stockholders’ equity (deficit)	$ 7,902,830	$ 13,267,121

CONDENSED BALANCE SHEETS _Paren

CONDENSED BALANCE SHEETS [Parenthetical] - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000	300,000,000
Common stock, shares issued	172,841,047	172,683,342
Common stock, shares outstanding	172,841,047	172,683,342

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue:
Genetic testing	$ 248,873	$ 439,400	$ 921,610	$ 1,342,947
Other	47,125	32,751	153,651	145,365
Total revenue	295,998	472,151	1,075,261	1,488,312
Cost of revenue	323,136	358,578	985,732	1,115,095
Gross profit	(27,138)	113,573	89,529	373,217
Operating expenses:
Research and development	411,902	242,142	978,970	666,839
Selling, general and administrative	1,413,702	1,305,583	4,631,718	4,338,245
Amortization of intangibles	19,414	23,525	58,242	70,575
Total operating expenses	1,845,018	1,571,250	5,668,930	5,075,659
Loss from operations	(1,872,156)	(1,457,677)	(5,579,401)	(4,702,442)
Other income (expense):
Interest income	0	911	222	4,511
Interest expense	(153,354)	0	(456,311)	0
Total other income (expense)	(153,354)	911	(456,089)	4,511
Loss before income taxes	(2,025,510)	(1,456,766)	(6,035,490)	(4,697,931)
Benefit for income taxes	0	0	0	0
Net loss	$ (2,025,510)	$ (1,456,766)	$ (6,035,490)	$ (4,697,931)
Basic and diluted net loss per common share (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.04)
Weighted average common shares outstanding, basic and diluted (in shares)	172,841,047	122,548,292	172,788,286	122,515,671

CONDENSED STATEMENTS OF STOCKHO

CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2013	$ 5,253,222	$ 122,449	$ 119,885,371	$ (114,754,598)
Balance (in shares) at Dec. 31, 2013		122,448,707
Net loss	(4,697,931)	$ 0	0	(4,697,931)
Common stock issued:
Employee stock purchase plan	27,557	$ 101	27,456	0
Employee stock purchase plan (in shares)		99,585
Stock-based compensation expense	354,441	$ 0	354,441	0
Balance at Sep. 30, 2014	937,289	$ 122,550	120,267,268	(119,452,529)
Balance (in shares) at Sep. 30, 2014		122,548,292
Balance at Dec. 31, 2013	5,253,222	$ 122,449	119,885,371	(114,754,598)
Balance (in shares) at Dec. 31, 2013		122,448,707
Net loss	6,300,000
Balance at Dec. 31, 2014	4,516,857	$ 172,686	125,434,483	(121,090,312)
Balance (in shares) at Dec. 31, 2014		172,683,342
Net loss	(6,035,490)	$ 0	0	(6,035,490)
Common stock issued:
Private Placement	(7,100)		(7,100)
Horizon Warrant	11,848		11,848
Employee stock purchase plan	16,799	$ 157	16,642	0
Employee stock purchase plan (in shares)		157,705
Stock-based compensation expense	651,791	$ 0	651,791	0
Balance at Sep. 30, 2015	$ (845,295)	$ 172,843	$ 126,107,664	$ (127,125,802)
Balance (in shares) at Sep. 30, 2015		172,841,047

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,035,490)	$ (4,697,931)
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation and amortization	214,180	190,012
Amortization of loan issuance costs and FV of warrants	81,908	0
Stock-based compensation expense	651,791	354,441
Changes in operating assets and liabilities:
Accounts receivable	8,708	(5,926)
Receivable from related party	(17,059)	499,987
Inventory	12,482	23,248
Prepaid expenses and other current assets	(26,909)	115,005
Accounts payable	62,283	(537,561)
Accrued expenses	112,074	(62,224)
Deferred revenue	(228,773)	(752,212)
Net cash used in operating activities	(5,164,805)	(4,873,161)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital additions	(41,057)	(92,278)
Net cash used in investing activities	(41,057)	(92,278)
CASH FLOWS FROM FINANCING ACTIVITIES:
Private placement offering costs	(7,100)	0
Proceeds from employee stock purchase plan	16,799	27,557
Net cash provided by financing activities	9,699	27,557
Net (decrease) in cash and cash equivalents	(5,196,163)	(4,937,882)
Cash and cash equivalents, beginning of period	11,466,807	7,542,281
Cash and cash equivalents, end of period	6,270,644	2,604,399
Supplemental disclosures of cash flow information:
Cash paid for interest	$ 352,500	$ 0

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 1—Basis of Presentation Interleukin Genetics, Inc. (“the Company”) develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive or therapeutic measures. The Company’s principal operations and markets are located in the United States. The accompanying condensed financial statements include the accounts of the Company as of September 30, 2015 and December 31, 2014 and for the three and nine months ended September 30, 2015 and 2014. The financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial reporting. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. These unaudited condensed financial statements, which, in the opinion of management, reflect all adjustments (including normal recurring adjustments) necessary for a fair presentation, should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Operating results are not necessarily indicative of the results that may be expected for any future interim period or for the entire 2015 fiscal year. For information regarding our critical accounting policies and estimates, please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates” contained in our Annual Report on Form 10-K for the year ended December 31, 2014 and Note 3 to our condensed financial statements contained herein.

Liquidity

Liquidity	9 Months Ended
	Sep. 30, 2015
Going Concern [Abstract]
Liquidity	Note 2—Liquidity The Company has experienced net operating losses since its inception through September 30, 2015. The Company had net losses of $ 6.3 6.04 127.1 On May 17, 2013, the Company entered into a Common Stock Purchase Agreement (the “2013 Purchase Agreement”) with various accredited investors (the “2013 Investors”), pursuant to which the Company sold securities to the 2013 Investors in a private placement transaction (the “May 2013 Private Placement”). In the May 2013 Private Placement, the Company sold an aggregate of 43,715,847 0.2745 12,000,000 32,786,885 0.2745 On December 23, 2014, the Company entered into a Securities Purchase Agreement (the “2014 Purchase Agreement”) with various accredited investors (the “2014 Investors”), pursuant to which the Company sold to the 2014 Investors in a private placement transaction (the “December 2014 Private Placement”) an aggregate of 50,099,700 0.1003 5.025 50,099,700 0.1003 On December 23, 2014, the Company entered into a Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation (the “Lender”) under which the Company has borrowed $ 5.0 The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month. 9.0 The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan will be due and payable. 2,492,523 0.1003 The Company’s financial statements have been prepared assuming that it will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company expects to incur additional losses in 2015 and, accordingly, is dependent on financings and potential revenue to fund its operations ® ® ® ® ® The Company expects to have the cash resources necessary to fund its operations into the second half of 2016. The ability of the Company to realize the carrying value of its fixed assets and intangible assets is dependent on management’s ability to successfully execute on its plan. The Company needs to generate additional funds in order to meet its financial obligations. If it is unsuccessful in doing so, the Company may not be able to realize the carrying value of its fixed assets and intangible assets.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3—Summary of Significant Accounting Policies The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates. The Company’s most critical accounting policies are more fully discussed in these notes to the financial statements. Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of September 30, 2015 and December 31, 2014, the Company had deferred genetic test revenue of $ 2.9 3.2 2.7 0.3 2.4 The Company recognizes breakage revenue related to genetic test kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. The Company analyzed redemption patterns from 2009 through 2014 and determined the period of time after which the likelihood of test redemption was remote was three years after the sale of a genetic test kit. Included in genetic test revenue in the three and nine months ended September 30, 2015 is $ 39,000 167,000 86,000 242,000 On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. (“Alticor”). Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health ® 70,000 59,000 239,000 160,000 Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2 Inventory is carried at lower of cost (first-in, first-out method) or market and no inventory reserve is deemed necessary at September 30, 2015. As the Company does not manufacture any products, no overhead costs are included in inventory. The Company has contracted with a fulfillment provider to supply its PerioPredict ® ® 33,000 ® ® September 30, 2015 December 31, 2014 Raw materials $ 142,351 $ 163,239 Finished goods 16,742 8,336 Total inventory, net $ 159,093 $ 171,575 The Company accounts for stock-based compensation expense in accordance with FASB ASC 718, Compensation – Stock Compensation Income Taxes Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $33.4 million as of September 30, 2015, due to uncertainties related to its ability to utilize these assets. The valuation allowance is based on management’s estimates of taxable income by jurisdiction in which the Company operates and the period over which the deferred tax assets will be recoverable. In the event that actual results differ from these estimates or management adjusts these estimates in future periods, the Company may need to adjust its valuation allowance, which could materially impact its financial position and results of operations. As a result of the Company’s change in its capital structure during the quarters ending June 30, 2013 and December 23, 2014, the Company may have undergone an IRC section 382 ownership change which would limit its ability to realize the benefit of its tax attributes (i.e., federal/state net operating losses and research and development credits) during their respective carry forward periods. Furthermore, pursuant to the change in capital structure, the Company realized cancellation of indebtedness income under IRC section 108(e)(8), which reduced the Company’s federal net operating loss carry-forward pursuant to IRC section 108(b)(2)(A), due to the fact that the Company’s liabilities exceeded the fair market value of its assets. Accordingly, the Company had a reduction in its deferred tax asset and a corresponding reduction in its valuation allowance for the quarter ending June 30, 2013. The cancellation of indebtedness income resulted from a shareholder’s conversion of debt of approximately $ 14.3 The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the nine months ended September 30, 2015. Research and development costs are expensed as incurred. The Company applies the provisions of FASB ASC 260, Earnings per Share As of September 30, 2015 2014 Options outstanding 22,258,659 4,810,675 Warrants outstanding 88,301,079 37,269,125 Total 110,559,738 42,079,800 The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. The fair value of warrants is calculated using the Black-Scholes pricing model. The Company maintains its cash and cash equivalents with domestic financial institutions that the Company believes to be of high credit standing. The Company believes that, as of September 30, 2015, its concentration of credit risk related to cash and cash equivalents was not significant. Cash and cash equivalents are available on demand and are generally in excess of FDIC insurance limits. Fixed assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease. Assets that have not yet been placed in service, have the costs incurred presented as part of Projects in Progress. Once the asset has been placed in service, the related costs are transferred to the appropriate category and depreciation commences. For the nine months ended September 30, 2015 there is $ 19,500 As of September 30, 2015 and 2014, the Company has one segment, the genetic test business. The Company develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company’s principal operations and markets are located in the United States. FASB ASU 2015-03 - Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. In April 2015, the FASB issued ASU No. 2015-03, which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts. Prior to the amendments, debt issuance costs were presented as a deferred charge (i.e., an asset) on the balance sheet. Further, the amendments require the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. The amendments are effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The amendments must be applied retrospectively. All entities have the option of adopting the new requirements as of an earlier date for financial statements that have not been previously issued. The Company does not expect this ASU to have a material impact on its consolidated financial statements. FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers. In May 2014, the FASB issued amended guidance on contracts with customers to transfer goods or services or contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The guidance requires an entity to recognize revenue on contracts with customers to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance requires that an entity depict the consideration by applying the following five steps: ⋅ Identify the contract(s) with a customer. ⋅ Identify the performance obligations in the contract. ⋅ Determine the transaction price. ⋅ Allocate the transaction price to the performance obligations in the contract. ⋅ Recognize revenue when (or as) the entity satisfies a performance obligation. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. This amendment is to be either retrospectively adopted to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In April 2015, the FASB voted to defer the required implementation date of ASU 2014-09 to December 2017. Public companies may elect to adopt the standard along the original timeline. We are evaluating the impact of the adoption of this guidance to determine whether or not it has a material impact on the Company's financial statements. FASB ASC 606 ASU 2014-15 - Presentation of Financial Statements—Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In August 2014, the FASB issued ASU No. 2014-15, which applies should a company be facing probable liquidation within one year of the issuance of the financial statements, but is not actually in liquidation at the time of issuance. The applicable basis for presentation remains as a going concern, but if liquidation within one year is probable, then certain disclosures must be included in the financial statement presentation. ASU 2014-15 is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. We are evaluating the impact of ASU 2014-15 on our financial disclosures, but are not electing early adoption at this time.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Note 4—Related Party Transactions Since March 2003, the Company has maintained a broad strategic alliance with several affiliates of the Alticor Inc. family of companies, a related party. The alliance initially included an equity investment, a multi-year research and development agreement, a licensing agreement with royalties on marketed products, the deferment of outstanding loan repayment and the refinancing of bridge financing obligations. On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health ® 70,000 59,000 239,000 160,000 Beginning in September 2012 and again in 2013, Access Business Group LLC (“ABG”), an affiliate of Alticor, placed purchase orders totaling approximately $3.3 million consisting of Weight Management test kits. The kits are included as part of a promotional bundle of products that Amway sold to their Individual Business Owners (IBOs). Of the $3.3 million in orders, $ 1.5 1.8 519,000 250,000 On September 21, 2012, the Company entered into a License Agreement with Access Business Group International LLC (“ABGI”), an affiliate of Alticor. Pursuant to the License Agreement, the Company has granted ABGI and its affiliates a non-exclusive license to use the technology related to Interleukin’s Weight Management genetic test and to sell the Weight Management test in Europe, Russia and South Africa (the “Territories”). ABGI, or a laboratory designated by ABGI, will be responsible for processing the tests, and the Company will receive a royalty for each test sold, which royalty will increase if certain pending patent applications are issued. The License Agreement has an initial term of five years from the date of first commercial sale of the Weight Management test under the agreement which was June 2013. Thereafter, the term will automatically renew for additional one-year periods unless notice is delivered by either party at least 60 39,000 143,000 31,000 129,000 In connection with the execution of the License Agreement, the Company and ABGI also entered into a Professional Services Agreement (the “PSA”) pursuant to which the Company has agreed to provide services to ABGI in connection with its sale and processing of the tests within the Territories. No fees were earned in the year ended December 31, 2014 or the nine months ended September 30, 2015 under the PSA. For the three months ended September 30, 2015 and 2014, approximately 45 48 14 30 49 41 15 35 On February 25, 2013, the Company entered into a Preferred Participation Agreement with Renaissance Health Services Corporation (“RHSC”), for itself and on behalf of certain of its affiliates and subsidiaries. This agreement was amended and restated on November 1, 2013. RHSC is a related party through its affiliation with Delta Dental of Michigan, Inc. (“DDMI”), a stockholder of the Company. ® ® ® unless terminated earlier . The timing of any revenues that the Company may receive under the amended agreement with RHSC is dependent upon the timing of the offering of Reimbursed Dental Plans and the subsequent adoption of such Reimbursed Dental Plans by RHSC customers, the timing of which is very uncertain at this time and is dependent on a viable market developing for such plans. RHSC has informed us that it has presented the scientific data underlying Reimbursed Dental Plans to a number of customers and will make available Reimbursed Dental Plans as an alternative to a customer’s current plan for any customer that expresses an interest in such a plan. The Company may never receive significant revenues under this agreement.

Debt Instruments

Debt Instruments	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt Instruments	Note 5—Debt Instruments Venture Loan and Security Agreement On December 23, 2014, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation (the “Lender”) under which the Company borrowed $ 5.0 The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month. 9.0 The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan, or $225,000, will be due and payable. 2,492,523 0.1003 10 Additionally, $ 89,000 261,000 225,000 280,000 115,000 341,000 38,000 115,000

Commitments and contingencies

Commitments and contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies [Abstract]
Commitments and contingencies	Note 6—Commitments and contingencies Operating Lease The Company leases its office and laboratory space under a non-cancelable operating lease which was originally scheduled to expire on March 31, 2014. In May 2010, the Company completed a sublease of 6,011 square feet of underutilized office and laboratory space and on March 31, 2014, the sublease expired. On February 7, 2014, the Company entered into the Second Amendment to Commercial Lease which, among other things a) extended the term of the lease from March 31, 2014 to March 31, 2017; b) reduced the 19,000 square feet, the amount of space under the master lease, by approximately 6,011 square feet, to approximately 13,000 square feet, which is the amount of space the Company currently occupies 2.06 2.06 Rent expense, net of the benefit of the sublease in 2014, was $ 96,000 80,000 268,000 230,000 Off-Balance Sheet Arrangements The Company has no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on its financial condition, results of operations or cash flows. Employment Agreements On April 6, 2015 the Company entered into an Executive Employment Agreement (the “Agreement”), pursuant to which Mark B. Carbeau was appointed as the Company’s Chief Executive Officer and a member of the Company’s Board of Directors. Effective upon Mr. Carbeau’s appointment, Dr. Kenneth S. Kornman resigned as Chief Executive Officer and remained as the Company’s President and Chief Scientific Officer. Pursuant to the Agreement, Mr. Carbeau will receive an initial annual base salary of $ 365,000 35 150 14,245,227 0.1525 25 2.083 The Agreement provides that if Mr. Carbeau’s employment with the Company is terminated for any reason other than Cause (as defined in the Agreement) and on execution of a release of claims agreement, he will be entitled to (i) severance payments equal to 12 months of base salary and (ii) continuation of medical benefits for up to 12 months. In addition to the above, if termination is within one year following a Change of Control event and is for any reason other than Cause, all outstanding unvested equity awards held by Mr. Carbeau will immediately vest and be exercisable. On November 12, 2008, the Company entered into an employment agreement with Dr. Kornman, its President and Chief Scientific Officer, for a three-year term, commencing on March 31, 2009, the date his previous employment agreement expired. Effective March 31, 2012, this agreement was extended through November 30, 2012, and was extended again on November 20, 2012 through November 30, 2015. Under this agreement, Dr. Kornman received an initial annual salary of $ 360,000 3,296 The agreement is terminable immediately by the Company with cause or upon thirty days prior written notice without cause. The agreement is terminable by Dr. Kornman upon thirty days prior written notice. If the Company terminates Dr. Kornman without cause or Dr. Kornman terminates his employment with good reason, then, in addition to payment of any accrued, but unpaid compensation prior to the termination, the Company must continue to pay his base salary and to provide health insurance benefits until the earlier of (1) expiration of the agreement or (2) twelve months. If the Company terminates Dr. Kornman in connection with a Cessation of the Company’s Business (as defined in the agreement), then, in addition to payment of any accrued, but unpaid compensation prior to the termination, the Company must continue to pay his base salary and to provide health insurance benefits until the earlier of (1) expiration of the agreement or (2) three months. The agreement also includes non-compete and non-solicitation provisions for a period of twelve months following the termination of Dr. Kornman’s employment. In April 2010, Dr. Kornman was issued an option to purchase 30,000 0.745 20 In May 2011, Dr. Kornman was issued an option to purchase 100,000 0.46 25 In December 2012, Dr. Kornman was issued an option to purchase 300,000 0.34 25 33 42 In October 2013, Dr. Kornman was issued an option to purchase 2,250,000 0.3799 25 2.08 In January 2015, Dr. Kornman was granted an option to purchase 2,030,000 0.26 On December 26, 2012, the Company entered into an employment agreement with Scott Snyder for the position of Chief Marketing Officer beginning on January 2, 2013. The agreement provides for a minimum annual base salary of $ 265,000 30 34,000 16,000 60,000 80,000 40,000 200,000 0.29 50,000 66,000 84,000 In October 2013, Mr. Snyder was issued an option to purchase 675,000 0.3799 25 2.08 In January 2015, Mr. Snyder was granted an option to purchase 660,000 0.26 Mr. Snyder’s employment with the Company terminated effective November 13, 2015. The Company will pay Mr. Snyder any compensation that is earned but unpaid prior to termination, and an amount equal to six months of his base salary in effect at the time of the termination with such payment made in equal installments on the Company’s regularly-scheduled payment dates. Per Mr. Snyder’s employment agreement, 84,000

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2015
Capital Stock [Abstract]
Capital Stock	Note 7—Capital Stock Authorized Preferred and Common Stock 6,000,000 0.001 450,000,000 0.001 300,000,000 450,000,000 172,841,047 Reserved Strike for issuance Price Expiry Shares reserved under outstanding stock options and options available for grant 52,311,279 Shares reserved for future issuance under the Employee Stock Purchase Plan 346,247 Warrants to purchase common stock associated with December 2014 private placement 50,189,431 $ 0.1003 December 23, 2021 Warrants to purchase common stock associated with December 2014 venture loan and security agreement 2,492,523 $ 0.1003 December 23, 2024 Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors 100,000 $ 0.2500 September 8, 2024 Outstanding warrants issued in June 2012 437,158 $ 0.2745 June 29, 2017 Outstanding warrants issued in May 2013, vesting May 2013 20,655,737 $ 0.2745 May 17, 2020 Outstanding warrants issued in May 2013, vesting August 2013 14,426,230 $ 0.2745 August 9, 2020 Total common shares reserved for issuance at September 30, 2015 140,958,605 Total common shares issued and outstanding at September 30, 2015 172,841,047 Total common shares outstanding and reserved for issuance at September 30, 2015 313,799,652 On May 17, 2013, the Company entered into the 2013 Purchase Agreement with the 2013 Investors, pursuant to which the Company sold securities to the 2013 Investors in the May 2013 Private Placement. In the May 2013 Private Placement, the Company sold an aggregate of 43,715,847 0.2745 12,000,000 32,786,885 0.2745 63 37 150,000,000 300,000,000 For its services in this transaction, the placement agent received cash compensation in the amount of approximately $ 780,000 2,295,082 0.2745 In September, 2014, the Company issued warrants to financial consultant, Danforth Advisors, to purchase up to 100,000 0.25 if the Company terminates the agreement without cause before the one year anniversary, 50 24,000 3,000 9,000 On December 23, 2014, the Company entered into the 2014 Purchase Agreement with the 2014 Investors, pursuant to which it sold to the 2014 Investors in the December 2014 Private Placement an aggregate of 50,099,700 0.1003 5.025 50,099,700 0.1003 For services related to this transaction, the placement agent and legal counsel received an aggregate of $ 218,000 89,731 December 23, 2014 Risk-free interest rate 1.98 % Expected life 7 years Expected volatility 138.4 % Dividend yield 0 % On the closing date of the December 2014 Private Placement, the fair value of the 2014 Warrants was $ 5.2 9,000 Registration Rights Agreement In connection with the December 2014 Private Placement, on December 23, 2014, the Company also entered into a Registration Rights Agreement with the 2014 Investors and the placement agent, pursuant to which the Company was required to file a registration statement on Form S-1 within 45 days of December 23, 2014 to cover the resale of (i) the shares of common stock sold to the 2014 Investors and the shares of common stock underlying the 2014 Warrants and (ii) the shares of common stock underlying the 2014 Placement Agent Warrants. The Company filed the registration statement on February 6, 2015, and it was declared effective on March 31, 2015. Venture Loan and Security Agreement On December 23, 2014, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation (the “Lender”) under which the Company has borrowed $ 5.0 2,492,523 0.1003 December 23, 2014 Risk-free interest rate 2.17 % Expected life 10 years Expected volatility 121.6 % Dividend yield 0 % The fair value of the Lender Warrants at issuance was $ 261,000 115,000 353,000 38,000 115,000 280,000

Stock-Based Compensation Arrang

Stock-Based Compensation Arrangements	9 Months Ended
	Sep. 30, 2015
Stock-Based Compensation Arrangements [Abstract]
Stock-Based Compensation Arrangements	Note 8—Stock-Based Compensation Arrangements Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Stock option grants beginning of period $ 251,374 $ 108,363 $ 491,197 $ 348,545 Stock-based arrangements during the period: Stock option grants 92 — 157,463 1,166 Restricted stock issued: Employee stock purchase plan 1,088 1,279 3,129 4,730 $ 252,554 $ 109,642 $ 651,789 $ 354,441 Stock option and restricted stock grants Nine Months Ended Nine Months Ended September 30, 2015 September 30, 2014 Weighted Avg Weighted Avg Exercise Exercise Shares Price Shares Price Outstanding, beginning of period 4,523,900 $ 0.39 5,884,050 $ 0.43 Stock options granted 17,793,027 0.17 137,000 0.35 Stock options exercised — 0.00 — 0.00 Restricted stock exercised — 0.00 — 0.00 Canceled/Expired (58,268) 0.28 (1,210,375) 0.43 Outstanding, end of period 22,258,659 $ 0.22 4,810,675 $ 0.43 Exercisable, end of period 3,067,959 $ 0.34 723,925 $ 0.71 At September 30, 2015, there was approximately $ 2,700,000 Restricted Stock Awards At September 30, 2015 and 2014, there were no outstanding restricted stock awards. Stock Option Grants On August 9, 2013, the Company’s shareholders’ approved the 2013 Employee, Director and Consultant Equity Incentive Plan (the “2013 Plan”). The 2013 Plan allows for the issuance of up to 8,860,000 2,435,500 6,170,748 30,000,000 30,052,620 Pursuant to his Employment Agreement on April 6, 2015, Mr. Carbeau was granted options to purchase up to 14,245,227 0.1525 2,622,948 11,622,279 It is the Company’s policy to grant stock options with an exercise price equal to the fair market value of the Company’s common stock at the grant date, and stock options to employees generally vest over four years based upon continuous service. Historically, the majority of the Company’s stock options have been granted in connection with the employee’s start date with the Company. In addition, the Company may grant stock options in recognition of promotion and/or performance. Employee Stock Purchase Plan Purchases made under the Company’s Employee Stock Purchase Plan are deemed to be compensatory because employees may purchase stock at a price equal to 85 157,705 99,585 0.10 0.28 0.12 0.32 3,129 4,730

Industry Risk and Concentration

Industry Risk and Concentration	9 Months Ended
	Sep. 30, 2015
Risks and Uncertainties [Abstract]
Industry Risk and Concentration	Note 9—Industry Risk and Concentration The Company develops genetic risk assessment tests and performs research for its own benefit. As of September 30, 2015, the Company sells five genetic risk assessment tests. Commercial success of the Company’s genetic risk assessment tests will depend on their success as being deemed to be scientifically credible and cost-effective by consumers and the marketing success of the Company and its collaborative partners. Research in the field of disease predisposing genes and genetic markers is intense and highly competitive. The Company has many competitors in the United States and abroad that have considerably greater financial, technical, marketing, and other resources available. If the Company does not discover disease predisposing genes or genetic markers and develop risk assessment tests and launch such services or products before its competitors, then the potential for significant revenues may be reduced or eliminated. During the three months ended September 30, 2015 and 2014, approximately 45 48 14 30 49 41 15

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Event	Note 10—Subsequent Events On November 13, 2015, the employment of Mr. Scott Snyder, formerly Chief Marketing Officer

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Significant Accounting Policies [Abstract]
Management Estimates	Management Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates. The Company’s most critical accounting policies are more fully discussed in these notes to the financial statements.
Revenue Recognition	Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of September 30, 2015 and December 31, 2014, the Company had deferred genetic test revenue of $ 2.9 3.2 2.7 0.3 2.4 The Company recognizes breakage revenue related to genetic test kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. The Company analyzed redemption patterns from 2009 through 2014 and determined the period of time after which the likelihood of test redemption was remote was three years after the sale of a genetic test kit. Included in genetic test revenue in the three and nine months ended September 30, 2015 is $ 39,000 167,000 86,000 242,000
Sales Commissions	Sales Commission On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. (“Alticor”). Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health ® 70,000 59,000 239,000 160,000
Accounts Receivable	Accounts Receivable Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2
Inventory	Inventory Inventory is carried at lower of cost (first-in, first-out method) or market and no inventory reserve is deemed necessary at September 30, 2015. As the Company does not manufacture any products, no overhead costs are included in inventory. The Company has contracted with a fulfillment provider to supply its PerioPredict ® ® 33,000 ® ® September 30, 2015 December 31, 2014 Raw materials $ 142,351 $ 163,239 Finished goods 16,742 8,336 Total inventory, net $ 159,093 $ 171,575
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation expense in accordance with FASB ASC 718, Compensation – Stock Compensation
Income Taxes	Income Taxes Income Taxes Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $33.4 million as of September 30, 2015, due to uncertainties related to its ability to utilize these assets. The valuation allowance is based on management’s estimates of taxable income by jurisdiction in which the Company operates and the period over which the deferred tax assets will be recoverable. In the event that actual results differ from these estimates or management adjusts these estimates in future periods, the Company may need to adjust its valuation allowance, which could materially impact its financial position and results of operations. As a result of the Company’s change in its capital structure during the quarters ending June 30, 2013 and December 23, 2014, the Company may have undergone an IRC section 382 ownership change which would limit its ability to realize the benefit of its tax attributes (i.e., federal/state net operating losses and research and development credits) during their respective carry forward periods. Furthermore, pursuant to the change in capital structure, the Company realized cancellation of indebtedness income under IRC section 108(e)(8), which reduced the Company’s federal net operating loss carry-forward pursuant to IRC section 108(b)(2)(A), due to the fact that the Company’s liabilities exceeded the fair market value of its assets. Accordingly, the Company had a reduction in its deferred tax asset and a corresponding reduction in its valuation allowance for the quarter ending June 30, 2013. The cancellation of indebtedness income resulted from a shareholder’s conversion of debt of approximately $ 14.3 The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the nine months ended September 30, 2015.
Research and Development	Research and Development Research and development costs are expensed as incurred.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share The Company applies the provisions of FASB ASC 260, Earnings per Share As of September 30, 2015 2014 Options outstanding 22,258,659 4,810,675 Warrants outstanding 88,301,079 37,269,125 Total 110,559,738 42,079,800
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. The fair value of warrants is calculated using the Black-Scholes pricing model.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company maintains its cash and cash equivalents with domestic financial institutions that the Company believes to be of high credit standing. The Company believes that, as of September 30, 2015, its concentration of credit risk related to cash and cash equivalents was not significant. Cash and cash equivalents are available on demand and are generally in excess of FDIC insurance limits.
Fixed Assets	Fixed Assets Fixed assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease. Assets that have not yet been placed in service, have the costs incurred presented as part of Projects in Progress. Once the asset has been placed in service, the related costs are transferred to the appropriate category and depreciation commences. For the nine months ended September 30, 2015 there is $ 19,500
Segment Reporting	Segment Reporting As of September 30, 2015 and 2014, the Company has one segment, the genetic test business. The Company develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company’s principal operations and markets are located in the United States.
Recent Accounting Pronouncements	Recent Accounting Pronouncements FASB ASU 2015-03 - Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. In April 2015, the FASB issued ASU No. 2015-03, which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts. Prior to the amendments, debt issuance costs were presented as a deferred charge (i.e., an asset) on the balance sheet. Further, the amendments require the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. The amendments are effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The amendments must be applied retrospectively. All entities have the option of adopting the new requirements as of an earlier date for financial statements that have not been previously issued. The Company does not expect this ASU to have a material impact on its consolidated financial statements. FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers. In May 2014, the FASB issued amended guidance on contracts with customers to transfer goods or services or contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The guidance requires an entity to recognize revenue on contracts with customers to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance requires that an entity depict the consideration by applying the following five steps: ⋅ Identify the contract(s) with a customer. ⋅ Identify the performance obligations in the contract. ⋅ Determine the transaction price. ⋅ Allocate the transaction price to the performance obligations in the contract. ⋅ Recognize revenue when (or as) the entity satisfies a performance obligation. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. This amendment is to be either retrospectively adopted to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In April 2015, the FASB voted to defer the required implementation date of ASU 2014-09 to December 2017. Public companies may elect to adopt the standard along the original timeline. We are evaluating the impact of the adoption of this guidance to determine whether or not it has a material impact on the Company's financial statements. FASB ASC 606 ASU 2014-15 - Presentation of Financial Statements—Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In August 2014, the FASB issued ASU No. 2014-15, which applies should a company be facing probable liquidation within one year of the issuance of the financial statements, but is not actually in liquidation at the time of issuance. The applicable basis for presentation remains as a going concern, but if liquidation within one year is probable, then certain disclosures must be included in the financial statement presentation. ASU 2014-15 is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. We are evaluating the impact of ASU 2014-15 on our financial disclosures, but are not electing early adoption at this time.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2015
Significant Accounting Policies [Abstract]
Inventory	Inventory consisted of the following: September 30, 2015 December 31, 2014 Raw materials $ 142,351 $ 163,239 Finished goods 16,742 8,336 Total inventory, net $ 159,093 $ 171,575
Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share	Potential common stock equivalents excluded from the calculation of diluted net loss per share are as follows: As of September 30, 2015 2014 Options outstanding 22,258,659 4,810,675 Warrants outstanding 88,301,079 37,269,125 Total 110,559,738 42,079,800

Capital Stock (Tables)

Capital Stock (Tables)	9 Months Ended
	Sep. 30, 2015
Authorized, Issued and Reserved shares of common stock	6,000,000 0.001 450,000,000 0.001 300,000,000 172,841,047 Reserved Strike for issuance Price Expiry Shares reserved under outstanding stock options and options available for grant 52,311,279 Shares reserved for future issuance under the Employee Stock Purchase Plan 346,247 Warrants to purchase common stock associated with December 2014 private placement 50,189,431 $ 0.1003 December 23, 2021 Warrants to purchase common stock associated with December 2014 venture loan and security agreement 2,492,523 $ 0.1003 December 23, 2024 Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors 100,000 $ 0.2500 September 8, 2024 Outstanding warrants issued in June 2012 437,158 $ 0.2745 June 29, 2017 Outstanding warrants issued in May 2013, vesting May 2013 20,655,737 $ 0.2745 May 17, 2020 Outstanding warrants issued in May 2013, vesting August 2013 14,426,230 $ 0.2745 August 9, 2020 Total common shares reserved for issuance at September 30, 2015 140,958,605 Total common shares issued and outstanding at September 30, 2015 172,841,047 Total common shares outstanding and reserved for issuance at September 30, 2015 313,799,652
Placement Agent Warrants 2014 [Member]
Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants	The 2014 Warrants (and the 2014 Placement Agent Warrants) were recorded as equity at fair value on the date of issuance. Fair value of the 2014 Warrants (and the 2014 Placement Agent Warrants) was calculated using the following inputs in a Black-Scholes model: December 23, 2014 Risk-free interest rate 1.98 % Expected life 7 years Expected volatility 138.4 % Dividend yield 0 %
Lender Warrants [Member]
Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants	The Lender Warrants were recorded as equity at fair value on the date of issuance. Fair value of the Lender Warrants was calculated using the following inputs in a Black-Scholes model: December 23, 2014 Risk-free interest rate 2.17 % Expected life 10 years Expected volatility 121.6 % Dividend yield 0 %

Stock-Based Compensation Arra20

Stock-Based Compensation Arrangements (Tables)	9 Months Ended
	Sep. 30, 2015
Stock-Based Compensation Arrangements [Abstract]
Total Compensation Cost Recorded for Stock-Based Compensation	Total stock-based compensation is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Stock option grants beginning of period $ 251,374 $ 108,363 $ 491,197 $ 348,545 Stock-based arrangements during the period: Stock option grants 92 — 157,463 1,166 Restricted stock issued: Employee stock purchase plan 1,088 1,279 3,129 4,730 $ 252,554 $ 109,642 $ 651,789 $ 354,441
Schedule of Stock option activity	The following table details stock option activity: Nine Months Ended Nine Months Ended September 30, 2015 September 30, 2014 Weighted Avg Weighted Avg Exercise Exercise Shares Price Shares Price Outstanding, beginning of period 4,523,900 $ 0.39 5,884,050 $ 0.43 Stock options granted 17,793,027 0.17 137,000 0.35 Stock options exercised — 0.00 — 0.00 Restricted stock exercised — 0.00 — 0.00 Canceled/Expired (58,268) 0.28 (1,210,375) 0.43 Outstanding, end of period 22,258,659 $ 0.22 4,810,675 $ 0.43 Exercisable, end of period 3,067,959 $ 0.34 723,925 $ 0.71

Liquidity - Additional Informat

Liquidity - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 23, 2014	May. 17, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Line of Credit Facility [Line Items]
Net Income Loss			$ (2,025,510)	$ (1,456,766)	$ (6,035,490)	$ (4,697,931)	$ 6,300,000
Accumulated deficit			$ (127,125,802)		$ (127,125,802)		$ (121,090,312)
Venture Loan [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,492,523
Debt Instrument, Description of Variable Rate Basis	The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month.
Debt Instrument, Payment Terms	The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan will be due and payable.
Proceeds from Issuance of Long-term Debt	$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage	9.00%		9.00%		9.00%
Warrants Expire Term	10 years
December 2014 Private Placement [Member]
Line of Credit Facility [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	50,099,700
Sale of Stock, Price Per Share	$ 0.1003
Sale of Stock, Consideration Received on Transaction	$ 5,025,000
2013 Warrants [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.2745
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		32,786,885
Debt Instrument, Payment Terms		7 years
2014 warrants [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	50,099,700
Debt Instrument, Payment Terms	7 years
Common Stock [Member]
Line of Credit Facility [Line Items]
Net Income Loss					$ 0	$ 0
Sale of Stock, Consideration Received on Transaction		$ 12,000,000
Common Stock [Member] | May 2013 Private Placement [Member]
Line of Credit Facility [Line Items]
Sale of Stock, Number of Shares Issued in Transaction		43,715,847
Sale of Stock, Price Per Share		$ 0.2745
Sale of Stock, Consideration Received on Transaction		$ 12,000,000

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Schedule Of Inventory) (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Line Items]
Raw materials	$ 142,351	$ 163,239
Finished goods	16,742	8,336
Total inventory, net	$ 159,093	$ 171,575

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share) (Detail) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	110,559,738	42,079,800
Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	22,258,659	4,810,675
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	88,301,079	37,269,125

Summary of Significant Accoun24

Summary of Significant Accounting Policies- Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Deferred revenue	$ 2,900,000		$ 2,900,000		$ 3,200,000
Sales commissions	70,000	$ 59,000	$ 239,000	$ 160,000
Percentage of cash discount offered to customers			2.00%
Projects in Progress	19,500		$ 19,500
Convertible Debt	14,300,000		14,300,000
Fulfillment Center [Member]
Significant Accounting Policies [Line Items]
Payments To Acquire of Inventory			33,000
Genetic Test Revenue [Member]
Significant Accounting Policies [Line Items]
Breakage Revenue	39,000	$ 86,000	167,000	$ 242,000
Customer Payment [Member]
Significant Accounting Policies [Line Items]
Deferred revenue	300,000		300,000
Kits Components [Member]
Significant Accounting Policies [Line Items]
Deferred revenue	2,700,000		2,700,000
Distributors [Member]
Significant Accounting Policies [Line Items]
Deferred revenue	$ 2,400,000		$ 2,400,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Prior Period Notice				60 days
Business Combination, Consideration Transferred	$ 250,000
Amway Global [Member]
Business Acquisition [Line Items]
Commissions paid		$ 70,000	$ 59,000	$ 239,000	$ 160,000
Amway Global [Member] | Sales [Member]
Business Acquisition [Line Items]
Concentration Risk, Percentage		45.00%	48.00%	49.00%	41.00%
Access Business Group International Llc [Member]
Business Acquisition [Line Items]
Proceeds from License Fees Received		$ 39,000	$ 31,000	$ 143,000	$ 129,000
ABG [Member]
Business Acquisition [Line Items]
Purchase Order Placed				$ 519,000
ABG [Member] | Sales [Member]
Business Acquisition [Line Items]
Concentration Risk, Percentage		14.00%	30.00%	15.00%	35.00%
ABG [Member] | 2014 Program [Member]
Business Acquisition [Line Items]
Purchase Order Received						$ 1,800,000
ABG [Member] | 2013 Program [Member]
Business Acquisition [Line Items]
Purchase Order Received						$ 1,500,000

Debt Instruments - Additional I

Debt Instruments - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Dec. 23, 2014	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Debt Instrument [Line Items]
Interest Paid			$ 352,500	$ 0
Venture Loan [Member]
Debt Instrument [Line Items]
Proceeds from Issuance of Long-term Debt	$ 5,000,000
Debt Instrument, Description of Variable Rate Basis	The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month.
Debt Instrument, Interest Rate, Stated Percentage	9.00%	9.00%	9.00%
Debt Instrument, Payment Terms	The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan will be due and payable.
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,492,523
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.1003
Warrants Expire Term	10 years
Interest Expense, Debt	$ 89,000
Intrinsic Value Of Warrants	261,000
Interest Expense, Other	$ 225,000
Debt Instrument, Unamortized Discount		$ 280,000	$ 280,000
Interest Paid		115,000	341,000
Paid-in-Kind Interest		$ 38,000	$ 115,000

Commitments and contingencies -

Commitments and contingencies - Additional Information (Detail) - USD ($)	Nov. 13, 2015	Apr. 06, 2015	Jan. 02, 2013	Jan. 31, 2015	Oct. 31, 2013	Jul. 31, 2013	Dec. 31, 2012	May. 31, 2011	Apr. 30, 2010	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Loss Contingencies [Line Items]
Operating Leases, Rent Expense										$ 96,000	$ 80,000	$ 268,000	$ 230,000
Property Under Commercial Lease And Sublease Details												On February 7, 2014, the Company entered into the Second Amendment to Commercial Lease which, among other things a) extended the term of the lease from March 31, 2014 to March 31, 2017; b) reduced the 19,000 square feet, the amount of space under the master lease, by approximately 6,011 square feet, to approximately 13,000 square feet, which is the amount of space the Company currently occupies
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross					675,000
Granted, Weighted Avg.Exercise Price												$ 0.17	$ 0.35
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price										$ 0.34	$ 0.71	$ 0.34	$ 0.71
Operating Leases Base rent In Year Two												2.06%
Operating Leases Base Rent In Year Three												2.06%
Dr. Kornman [Member]
Loss Contingencies [Line Items]
Officers' Compensation												$ 360,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross				2,030,000	2,250,000		300,000	100,000	30,000
Granted, Weighted Avg.Exercise Price				$ 0.26	$ 0.3799
Annual Reimbursement For Payment Of Life Insurance Premiums												3,296
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price							$ 0.34	$ 0.46	$ 0.745
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					2.08%			25.00%	20.00%
Dr. Kornman [Member] | First Anniversaries [Member]
Loss Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					25.00%		25.00%
Dr. Kornman [Member] | Second Anniversaries [Member]
Loss Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							33.00%
Dr. Kornman [Member] | Third Anniversaries [Member]
Loss Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							42.00%
Chief Marketing Officer [Member]
Loss Contingencies [Line Items]
Officers' Compensation							$ 265,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross			200,000	660,000
Granted, Weighted Avg.Exercise Price			$ 0.29	$ 0.26
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					2.08%
Maximum Percentage Of Bonus On Annual Salary							30.00%
Maximum Reimbursement Expenses						$ 60,000	$ 34,000						$ 16,000
Travel and Entertainment Expense												$ 40,000		$ 80,000
Chief Marketing Officer [Member] | First Anniversaries [Member]
Loss Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			50,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					25.00%
Chief Marketing Officer [Member] | Second Anniversaries [Member]
Loss Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			66,000
Chief Marketing Officer [Member] | Third Anniversaries [Member]
Loss Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			84,000
Subsequent Event [Member]
Loss Contingencies [Line Items]
Shares Unvested Related Shares Granted	84,000
Chief Executive Officer [Member]
Loss Contingencies [Line Items]
Officers' Compensation		$ 365,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross		14,245,227
Granted, Weighted Avg.Exercise Price		$ 0.1525
Percentage Of Bonus On Base Salary For Executives		35.00%
Percentage Of Stretch Bonus Of Target Bonus		150.00%
Percentage Of Shares To Be Vest		25.00%
Percentage Of Additional Shares To Be Vest		2.083%

Capital Stock (Authorized, Issu

Capital Stock (Authorized, Issued and Reserved shares of common stock) (Detail)	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Reserved for issuance	140,958,605
Total common shares issued and outstanding at September 30, 2015	172,841,047
Total common shares outstanding and reserved for issuance at September 30, 2015	313,799,652
Warrants with common stock additional purchase rights associated with December 2014 private placement [Member]
Reserved for issuance	50,189,431
Strike Price | $ / shares	$ 0.1003
Expiry	Dec. 23, 2021
Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors [Member]
Reserved for issuance	100,000
Strike Price | $ / shares	$ 0.2500
Expiry	Sep. 8, 2024
Shares reserved under outstanding stock options and options available for grant [Member]
Reserved for issuance	52,311,279
Rights Associated With Employee Stock Purchase Plan [Member]
Reserved for issuance	346,247
Warrants to purchase common stock associated with December 2014 venture loan and security agreement [Member]
Reserved for issuance	2,492,523
Strike Price | $ / shares	$ 0.1003
Expiry	Dec. 23, 2024
Warrant Two [Member]
Reserved for issuance	437,158
Strike Price | $ / shares	$ 0.2745
Expiry	Jun. 29, 2017
Warrant Three [Member]
Reserved for issuance	20,655,737
Strike Price | $ / shares	$ 0.2745
Expiry	May 17, 2020
Warrant Four [Member]
Reserved for issuance	14,426,230
Strike Price | $ / shares	$ 0.2745
Expiry	Aug. 9, 2020

Capital Stock (Black Scholes mo

Capital Stock (Black Scholes model to determine the fair value of the warrants) (Detail)	1 Months Ended
	Dec. 23, 2014
2014 Placement Agent Warrants [Member]
Stockholders Equity [Line Items]
Risk-free interest rate	1.98%
Expected life	7 years
Expected volatility	138.40%
Dividend Yield	0.00%
Lender Warrants [Member]
Stockholders Equity [Line Items]
Risk-free interest rate	2.17%
Expected life	10 years
Expected volatility	121.60%
Dividend Yield	0.00%

Capital Stock - Additional Info

Capital Stock - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended	9 Months Ended
	Dec. 23, 2014	Sep. 30, 2014	May. 17, 2013	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Aug. 09, 2013
Stockholders Equity [Line Items]
Convertible preferred stock, par value				$ 0.001	$ 0.001
Convertible preferred stock, shares authorized				6,000,000	6,000,000
Common stock, shares authorized				450,000,000	450,000,000		300,000,000
Common stock, par value				$ 0.001	$ 0.001		$ 0.001
Common stock, shares outstanding				172,841,047	172,841,047		172,683,342
Allocated Share-based Compensation Expense				$ 3,000	$ 9,000
Common Stock Shares Issued				172,841,047	172,841,047		172,683,342
Common Stock Par Or Stated Value Per Share				$ 0.001	$ 0.001		$ 0.001
Interest Paid					$ 352,500	$ 0
May 2013 Private Placement [Member] | Minimum [Member]
Stockholders Equity [Line Items]
Common stock, shares authorized								150,000,000
May 2013 Private Placement [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Common stock, shares authorized								300,000,000
Venture Loan [Member]
Stockholders Equity [Line Items]
Warrants exercise price per share	$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,492,523
Warrants and Rights Outstanding	$ 261,000
Proceeds from Issuance of Long-term Debt	5,000,000
Interest Paid				$ 115,000	341,000
Paid-in-Kind Interest				38,000	115,000
Debt Instrument, Unamortized Discount				$ 280,000	280,000
Investor [Member]
Stockholders Equity [Line Items]
Sale of Stock, Consideration Received on Transaction	$ 5,025,000
Sale of Stock, Number of Shares Issued in Transaction	50,099,700
Warrants exercise price per share	$ 0.1003
Sale of Stock, Price Per Share	$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	50,099,700
Danforth Advisors [Member]
Stockholders Equity [Line Items]
Common stock, par value		$ 0.25				$ 0.25
Warrants Fair Value Disclosure		$ 24,000				$ 24,000
Common Stock Shares Issued		100,000				100,000
Common Stock Par Or Stated Value Per Share		$ 0.25				$ 0.25
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%
Common Stock [Member]
Stockholders Equity [Line Items]
Sale of Stock, Consideration Received on Transaction			$ 12,000,000
Common Stock [Member] | May 2013 Private Placement [Member]
Stockholders Equity [Line Items]
Sale of Stock, Consideration Received on Transaction			$ 12,000,000
Sale of Stock, Number of Shares Issued in Transaction			43,715,847
Sale of Stock, Price Per Share			$ 0.2745
Warrants 2013 [Member]
Stockholders Equity [Line Items]
Percentage Of Warrants Exercisable			63.00%
Percentage Of Warrants Exercisable After Shareholder Approval			37.00%
Warrants exercise price per share			$ 0.2745
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			32,786,885
Warrants 2014 [Member]
Stockholders Equity [Line Items]
Warrants and Rights Outstanding							$ 5,200,000
Placement Agent Warrants [Member]
Stockholders Equity [Line Items]
Allocated Share-based Compensation Expense					$ 780,000
Warrants To Purchase Of Common Stock					2,295,082
Warrants exercise price per share				$ 0.2745	$ 0.2745
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				89,731	89,731
Warrants and Rights Outstanding							$ 9,000
Payments for Underwriting Expense					$ 218,000

Stock-Based Compensation Arra31

Stock-Based Compensation Arrangements (Stock-Based Compensation) (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation	$ 252,554	$ 109,642	$ 651,789	$ 354,441
Stock option grants beginning of period [Member]
Share-based Compensation	251,374	108,363	491,197	348,545
Stock option grants [Member]
Share-based Compensation	92	0	157,463	1,166
Employee Stock Purchase Plan [Member]
Share-based Compensation	$ 1,088	$ 1,279	$ 3,129	$ 4,730

Stock-Based Compensation Arra32

Stock-Based Compensation Arrangements (Stock Option and Restricted Stock Grants) (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Shares
Outstanding, beginning of period	4,523,900	5,884,050
Stock options granted	17,793,027	137,000
Stock options exercised	0	0
Restricted stock exercised	0	0
Canceled/Expired	(58,268)	(1,210,375)
Outstanding, end of period	22,258,659	4,810,675
Exercisable, end of period	3,067,959	723,925
Weighted Avg. Exercise Price
Outstanding, beginning of period	$ 0.39	$ 0.43
Stock options granted	0.17	0.35
Stock options exercised	0	0
Restricted stock exercised	0	0
Canceled/Expired	0.28	0.43
Outstanding, end of period	0.22	0.43
Exercisable, end of period	$ 0.34	$ 0.71

Stock-Based Compensation Arra33

Stock-Based Compensation Arrangements - Additional Information (Detail) - USD ($)	Apr. 06, 2015	Jul. 21, 2015	Oct. 31, 2013	Sep. 30, 2015	Sep. 30, 2014	Aug. 09, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options				$ 2,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			675,000
Granted,Weighted Avg.Exercise Price				$ 0.17	$ 0.35
Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	14,245,227
Granted,Weighted Avg.Exercise Price	$ 0.1525
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				The options will vest as to 25% of the shares on April 6, 2016, and as to an additional 2.083% of the shares on the last day of each successive month thereafter, provided that he remains employed by Company on the vesting date.
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans				157,705	99,585
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock purchase price				85.00%
Weighted-average purchase price				$ 0.10	$ 0.28
Weighted-average fair value				$ 0.12	$ 0.32
Compensation expense				$ 3,129	$ 4,730
Employee Stock Purchase Plan [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans				157,705	99,585
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Payment Award, Number of Shares Authorized						8,860,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		30,000,000		6,170,748
2013 Plan [Member] | Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,622,948
2013 Plan [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				30,052,620
2004 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Payment Award, Number of Shares Authorized						2,435,500
Outside of 2013 Plan [Member] | Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	11,622,279

Industry Risk and Concentrati34

Industry Risk and Concentration - Additional Information (Detail) - Sales Revenue, Net [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Amway Global [Member]
Sales Revenue Goods Net Percentage	45.00%	48.00%	49.00%	41.00%
ABG’s Promotional Product Bundle Program [Member]
Sales Revenue Goods Net Percentage	14.00%	30.00%	15.00%	35.00%